Evidence map›Paper›PMID 39473251›Full record

ArticleCurrent medicinal chemistry2026

Mechanism Exploration of Astaxanthin in the Treatment of Adriamycin-induced Cardiotoxicity based on Network Pharmacology and Experimental Validation.

Yu Zhu, Mengyao Chen, Lin Xie, Yijun Pan, Yuntian Yang, Guoxing Wan

Abstract read
PubMed Publisher
In one paragraph

Article in Current medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Yu ZhuDepartment of Research and Teaching, Renmin Hospital, Hubei University of Medicine, Shiyan, 442000, Hubei, China.
Mengyao ChenDepartment of Oncology, Renmin Hospital, Institute of Medicine and Nursing, Hubei University of Medicine, Shiyan, 442000, Hubei, China.
Lin XieDepartment of Oncology, Renmin Hospital, Institute of Medicine and Nursing, Hubei University of Medicine, Shiyan, 442000, Hubei, China.
Yijun PanDepartment of Oncology, Renmin Hospital, Hubei University of Medicine, Shiyan, 442000, Hubei, China.
Yuntian YangDepartment of Oncology, Renmin Hospital, Hubei University of Medicine, Shiyan, 442000, Hubei, China.
Guoxing WanDepartment of Oncology, Renmin Hospital, Hubei University of Medicine, Shiyan, 442000, Hubei, China.

Funding

College Student Innovation and Entrepreneurship Training Program X202210929033Discipline Construction Foundation of Hubei University of Medicine X1204108National Natural Science Foundation of China 82204540
6 · The paper itself

Abstract

introductionAstaxanthin (AXT), a natural antioxidant recognized for its therapeutic potential in cancer and cardiovascular diseases, holds promise in mitigating adriamycin-induced cardiotoxicity (AIC). Nevertheless, the underlying mechanisms of AXT in AIC mitigation remain to be elucidated. Consequently, this study endeavors to elucidate the mechanism of AXT against AIC, employing an integrated approach.

methodsNetwork pharmacology, molecular docking, and molecular dynamics simulations were harnessed to explore the molecular mechanism underlying AXT's action against AIC. Furthermore, the

resultsA total of 533 putative AXT targets and 1478 AIC-related genes were initially screened by database retrieval and bioinformatics analysis. A total of 248 potential targets of AXT against AIC and several signaling pathways were identified by network pharmacology and enrichment analysis. Two core genes (CCL2 and NOS3) and the AGE-RAGE signaling pathway in diabetic complications were further highlighted by transcriptome validation based on the AIC in-vitro model. Additionally, molecular docking and dynamics analyses supported the robust binding affinity of AXT with the core targets.

conclusionThe study suggested that AXT might ameliorate AIC through the inhibition of CCL2 and NOS3 as well as AGE-RAGE signaling, which provide a theoretical basis for the development of a strategy against AIC.

Indexed as

CardiotoxicityDoxorubicinNetwork PharmacologyAnimalsHumansMolecular Docking SimulationMolecular Dynamics SimulationRatsXanthophyllsastaxanthineDoxorubicinXanthophyllsadriamycin-induced cardiotoxicityAstaxanthincardioprotection.molecular dockingmolecular dynamics simulationsnetwork pharmacologytranscriptome sequencing

Identifiers

PMID39473251

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.